Stock Events

Stock Events

Context Therapeutics 

€0.3080
32
-€0.00-1.28% Friday 19:47

Statistics

Day High
0.316
Day Low
0.298
52W High
2.94
52W Low
0.298
Volume
2,000
Avg. Volume
-
Mkt Cap
28.3M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q1 2026
Q2 2026
Next
-0.13
-0.11
-0.09
-0.08
Expected EPS
-0.0927753024
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-31.08MNet Income

Analyst Ratings

5.06Average Price Target
The highest estimate is 6.83.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6K9.STU. It's not an investment recommendation.
Plug Power
4
PLUG
Denison Mines
4
DNN
Invivyd
4
IVVD
Immunic
4
IMUX

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Puma Biotechnology
PBYI
Mkt Cap467.68M
Puma Biotechnology focuses on the development and commercialization of drugs for the treatment of various forms of cancer, directly competing with Context Therapeutics' oncology focus.
Macrogenics
MGNX
Mkt Cap263.08M
MacroGenics is a company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, closely aligning with Context Therapeutics' mission.
TG Therapeutics
TGTX
Mkt Cap8.26B
TG Therapeutics focuses on the development of novel treatments for B-cell malignancies and autoimmune diseases, competing in the broader oncology and therapeutic market.
Kura Oncology
KURA
Mkt Cap1.13B
Kura Oncology is engaged in the research and development of medications aimed at the treatment of cancer, directly competing in the oncology space.
Array Technologies
ARRY
Mkt Cap706.9M
Array BioPharma, acquired by Pfizer, focuses on the discovery, development, and commercialization of targeted small molecule drugs to treat cancer, making it a competitor in the oncology drug market.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation specializes in the discovery, development, and commercialization of proprietary therapeutics, with a strong focus on oncology, competing in the same therapeutic area as Context Therapeutics.

About

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Show more...
CEO
Martin A. Lehr
Employees
15
Country
United States
ISIN
US21077P1084
WKN
000A3CWBU

Listings

STU
DE
6K9.STU
MU
DE
6K9.MU
XNAS
US
CNTX
BOATS
BOATS
CNTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Context Therapeutics stock price today?▼
The current price of 6K9.STU is €0.31 EUR — it has decreased by -1.28% in the past 24 hours. Watch Context Therapeutics stock price performance more closely on the chart.
What is Context Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Context Therapeutics stocks are traded under the ticker 6K9.STU.
Is Context Therapeutics stock price growing?▼
6K9.STU stock has fallen by -6.1% compared to the previous week, the month change is a -47.8% fall, over the last year Context Therapeutics has showed a -55.36% decrease.
What is Context Therapeutics market cap?▼
Today Context Therapeutics has the market capitalization of 28.3M
When is the next Context Therapeutics earnings date?▼
Context Therapeutics is going to release the next earnings report on November 11, 2026.
What were Context Therapeutics earnings last quarter?▼
6K9.STU earnings for the last quarter are -0.13 EUR per share, whereas the estimation was -0.08 EUR resulting in a -62.79% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Context Therapeutics revenue for the last year?▼
Context Therapeutics revenue for the last year amounts to 0 EUR.
What is Context Therapeutics net income for the last year?▼
6K9.STU net income for the last year is -31.08M EUR.
How many employees does Context Therapeutics have?▼
As of September 05, 2026, the company has 15 employees.
In which sector is Context Therapeutics located?▼
Context Therapeutics operates in the Health & Wellness sector.
When did Context Therapeutics complete a stock split?▼
Context Therapeutics has not had any recent stock splits.
Where is Context Therapeutics headquartered?▼
Context Therapeutics is headquartered in PHILADELPHIA, United States.